On a small cohort of melanoma patients treated with anti-PD-1, non-responders displayed a significantly higher proximity of CD68+ myeloid cells to CD8+ T cells compared to responders in pre-treatment and on-treatment biopsies (85). The gene discussed is CD68; the disease is melanoma.